Remove starch protein At the end of the last century, the theory of amyloid protein had already had many supporters, and Athena Neurosciences, a Los Angeles-based biotechnology company, took the lead in the process of targeting amyloid protein. Their strategy is simple but also very bold: Develop a vaccine to… Continue Reading Alzheimer’s disease drug development difficulties (4)

Three theories At the end of the last century, we had a clearer understanding of the disease characteristics of Alzheimer’s disease, such as plaque and tangles, neuronal death, and memory decline. But where did the disease come from and how did it start? Alzheimer’s disease progresses very slowly. There are… Continue Reading Alzheimer’s disease drug development difficulties (3)

The first drug From the early to the early 1960s, scopolamine was used as an analgesic for maternal delivery. Scopolamine traps people in a semi-anesthetic state, leaving the patient awake while losing the ability to sense pain. However, during the course of medication, doctors found an interesting phenomenon: After giving… Continue Reading Alzheimer’s disease drug development difficulties (2)

Lost memory On November 3, 1906, a psychiatrist from Munich, Alois Alzheimer, reported a strange case at the conference of psychiatrists in southwest Germany in Tübingen. After the report was over, the audience was silent. What he had hoped for was a heated discussion. After all, nearly 100 people sat… Continue Reading Alzheimer’s disease drug development difficulties (1)

On April 27, Roche announced that Roche and its holding company, Foundation Medicine, Inc., have signed a cooperation agreement with Dean Diagnostic Technology Group Co., Ltd. (hereinafter referred to as “Dean Diagnostics”). They will work together to promote the individualized treatment of cancer in China. According to the cooperation agreement,… Continue Reading Roche inspected Dean’s diagnosis and introduced “general genomic sequencing analysis service” to jointly promote the individualized diagnosis and treatment of Chinese tumors.

Some people on the Internet have consulted: You once mentioned that Shatan antihypertensive drugs have a protective effect on the kidneys, but you saw an article on the headline today that it has kidney damage. What is going on here? The full name of the sartans antihypertensive drugs is called… Continue Reading Does Sartan antihypertensive drugs protect the kidney or damage the kidney? Is it safe to use regularly?

At present, there are as many as 100 PD-1/PD-L1 projects in the world (China accounts for more than 1/4). This can not help but cause everyone’s doubts: Is it possible for the pharmaceutical industry to develop R&D projects in a certain target/disease area? Have you invested too much money? Prior… Continue Reading Is the pharmaceutical industry excessively investing in the research and development of cancer?

The protection of the right to health is particularly important. The patent system encourages the innovation and research and development of drugs, but the high price and market monopoly caused by the drug patent will prevent the patients from getting urgently needed drugs in time and fully, seriously threaten public… Continue Reading The first forcible imitation of the “Sofosbuvir” case in the world

High pressure (systolic blood pressure) is not too high and low (diastolic blood pressure) is high, mostly in young and middle-aged hypertension and workplace hypertension. 1. How is the systolic and diastolic pressure formed? The circulatory system of the human body includes the heart and blood vessels, which are connected… Continue Reading Systolic blood pressure is not too high, diastolic blood pressure is high. What antihypertensive drugs should be chosen?